Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADNP homeobox 2 (ADNP2) is a transcription factor belonging to the homeobox and zinc finger protein families, widely expressed with particularly high levels in the brain during development and adulthood. It is predicted to regulate gene transcription via RNA polymerase II specificity and may play key roles in nervous system development, neuronal survival, and stress response, especially in protecting against oxidative stress. ADNP2 expression imbalances are documented in neuropsychiatric and neurodevelopmental conditions, and altered expression levels may contribute to disease progression in disorders including schizophrenia and autism, possibly via effects on autophagy and anti-apoptotic signaling. Peripheral ADNP2 mRNA levels are being explored as biomarkers for Alzheimer’s disease. At present, there is no direct evidence that ADNP2 is a therapeutic target for pharmacological intervention, nor are there known drugs targeting this molecule.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADNP homeobox 2 (ADNP2).